Preview
Sign-in for full Details 
Sign-in free and Explore the Exciting World of BiomedExperts:
- Over 1.500.000 Profiles
- More than 1.800 Organizations worldwide
- State of the Art Network Visualizations
- Manage your own Profile
- Locate Experts in your Country/Region
- Locate Experts in your 1. and 2. Level Network
- Connect to Experts Worldwide
NetworkView
Jean-Marc Nabholtz
This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers
together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles
free of charge to researchers worldwide.
Research Profile (preview)
Disorders
Chemicals & Drugs
Procedures
Concepts & Ideas
Physiology
Sign-in to see full Profile
Network (preview)
9
Mackey, John
9
Smylie, Michael
8
Riva, Alessandro
7
Tonkin, Katia
7
Lindsay, Mary-Ann
6
Reese, David
6
GLIGOROV, Joseph
5
Buzdar, Aman
4
Au, Heather-Jane
3
Bonneterre, Jacques
3
Murawsky, Michael
3
Riva, Alessandro
2
Robertson, John
2
Piccart-Gebhart, Martine
2
Steinberg, M
Sign-in to see all Coauthors
Publications
Sign-in to see all Publications
Sign in free and see...
Visualized networks:
See your personal network in
sophisticated graphical views
GeoTargeted Searches:
Locate experts around the world
and connect with global collaborators
Research Profiles:
See the visualized research activity
of experts around the globe
Sign-in to see more
Geonetwork of Jean-Marc Nabholtz (preview)
Cities where this author has publications
Cities where co-authors of this author have publications
Sign-in to see more
All Publications
-
2009: Nabholtz Jean-Marc; Mouret-Reynier Marie-Ange; Durando Xavier; Van Praagh Isabelle; Al-Sukhun Sana; Ferriere Jean-Pierre; Chollet Philippe
Comparative review of anastrozole, letrozole and exemestane in the management of early breast cancer.
Expert opinion on pharmacotherapy 2009;10(9):1435-47.
-
2008: Nabholtz J M
Aromatase inhibitors in the management of early breast cancer.
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 2008;34(11):1199-207.
-
2008: Burzykowski Tomasz; Buyse Marc; Piccart-Gebhart Martine J; Sledge George; Carmichael James; Lück Hans-Joachim; Mackey John R; Nabholtz Jean-Marc; Paridaens Robert; Biganzoli Laura; Jassem Jacek; Bontenbal Marijke; Bonneterre Jacques; Chan Stephen; Basaran Gul Atalay; Therasse Patrick
Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(12):1987-92.
-
2008: Piccart-Gebhart Martine J; Burzykowski Tomasz; Buyse Marc; Sledge George; Carmichael James; Lück Hans-Joachim; Mackey John R; Nabholtz Jean-Marc; Paridaens Robert; Biganzoli Laura; Jassem Jacek; Bontenbal Marijke; Bonneterre Jacques; Chan Stephen; Basaran Gul Atalay; Therasse Patrick
Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(12):1980-6.
-
2006: Nabholtz Jean-Marc; Gligorov Joseph
The emerging role of aromatase inhibitors in the adjuvant management of breast cancer.
Reviews on recent clinical trials 2006;1(3):237-49.
-
2006: Buzdar A; Howell A; Cuzick J; Wale C; Distler W; Hoctin-Boes G; Houghton J; Locker G Y; Nabholtz J M
Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial.
The lancet oncology 2006;7(8):633-43.
-
2006: Buzdar Aman U; Guastalla Jean-Paul; Nabholtz Jean-Marc; Cuzick Jack; ATAC Trialists' Group
Impact of chemotherapy regimens prior to endocrine therapy: Results from the ATAC (Anastrozole and Tamoxifen, Alone or in Combination) trial.
Cancer 2006;107(3):472-80.
-
2006: Nabholtz Jean-Marc; Gligorov Joseph
Taxane therapy for early stage breast cancer.
Women's health (London, England) 2006;2(1):99-114.
-
2006: Nabholtz Jean-Marc; Gligorov Joseph
Cardiovascular safety profiles of aromatase inhibitors : a comparative review.
Drug safety : an international journal of medical toxicology and drug experience 2006;29(9):785-801.
-
2006: Nabholtz Jean-Marc
Role of anastrozole across the breast cancer continuum: from advanced to early disease and prevention.
Oncology 2006;70(1):1-12.
-
2005: Nabholtz Jean-Marc; Gligorov Joseph
Docetaxel in the treatment of breast cancer: current experience and future prospects.
Expert review of anticancer therapy 2005;5(4):613-33.
-
2005: Nabholtz Jean-Marc; Gligorov Joseph
Docetaxel/trastuzumab combination therapy for the treatment of breast cancer.
Expert opinion on pharmacotherapy 2005;6(9):1555-64.
-
2005: Conner-Spady B L; Cumming C; Nabholtz J-M; Jacobs P; Stewart D
A longitudinal prospective study of health-related quality of life in breast cancer patients following high-dose chemotherapy with autologous blood stem cell transplantation.
Bone marrow transplantation 2005;36(3):251-9.
-
2005: Nabholtz Jean-Marc; Gligorov Joseph
The role of taxanes in the treatment of breast cancer.
Expert opinion on pharmacotherapy 2005;6(7):1073-94.
-
2004: Nabholtz Jean-Marc
Changes in endocrine therapy: anastrozole and advanced breast cancer in postmenopausal women.
The American journal of hospice & palliative care 2004;21(6):457-65.
-
2004: Keller Alan M; Mennel Robert G; Georgoulias Vassilis A; Nabholtz Jean-Marc; Erazo Aura; Lluch Anna; Vogel Charles L; Kaufmann Manfred; von Minckwitz Gunther; Henderson I Craig; Mellars Lillian; Alland Leila; Tendler Craig
Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(19):3893-901.
-
2003: Nabholtz Jean-Marc; Vannetzel Jean-Michael; Llory Jean-Francois; Bouffette Patrick
Advances in the use of taxanes in the adjuvant therapy of breast cancer.
Clinical breast cancer 2003;4(3):187-92.
-
2003: Nabholtz Jean-Marc; Falkson Carla; Campos Daniel; Szanto Janos; Martin Miguel; Chan Stephen; Pienkowski Tadeuz; Zaluski Jerzy; Pinter Tamas; Krzakowski Maciej; Vorobiof Daniel; Leonard Robert; Kennedy Ian; Azli Nacer; Murawsky Michael; Riva Alessandro; Pouillart Pierre;
Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(6):968-75.
-
2003: Nabholtz Jean-Marc A
Docetaxel-anthracycline combinations in metastatic breast cancer.
Breast cancer research and treatment 2003;79 Suppl 1():S3-9.
-
2002: Buzdar Aman U; Robertson John F R; Eiermann Wolfgang; Nabholtz Jean-Marc
An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane.
Cancer 2002;95(9):2006-16.
-
2002: Nabholtz Jean-Marc; Reese David M; Lindsay Mary-Ann; Riva Alessandro
HER2-positive breast cancer: update on Breast Cancer International Research Group trials.
Clinical breast cancer 2002;3 Suppl 2():S75-9.
-
2002: Nabholtz Jean-Marc; Cantin Jacques; Chang Jose; Guevin Raymond; Patel Ravi; Tkaczuk Katherine; Vodvarka Pavel; Lindsay Mary-Ann; Reese David; Riva Alessandro; Mackey John
Phase III trial comparing granulocyte colony-stimulating factor to leridistim in the prevention of neutropenic complications in breast cancer patients treated with docetaxel/doxorubicin/cyclophosphamide: results of the BCIRG 004 trial.
Clinical breast cancer 2002;3(4):268-75.
-
2002: Nabholtz Jean-Marc; Reese David
Anastrozole in the management of breast cancer.
Expert opinion on pharmacotherapy 2002;3(9):1329-39.
-
2002: Nabholtz Jean-Marc; Reese David; Lindsay Mary-Ann; Riva Alessandro
Evidence for the use of chemotherapy in breast cancer.
International journal of clinical oncology / Japan Society of Clinical Oncology 2002;7(4):254-64.
-
2002: Nabholtz Jean-Marc A; Reese David M; Lindsay Mary-Ann; Riva Alessandro
Docetaxel in the treatment of breast cancer: an update on recent studies.
Seminars in oncology 2002;29(3 Suppl 12):28-34.
-
2002: Nabholtz Jean-Marc A; Reese David M; Lindsay Mary-Ann; Riva Alessandro
Combination chemotherapy for metastatic breast cancer.
Expert review of anticancer therapy 2002;2(2):169-80.
-
2001: Bonneterre J; Buzdar A; Nabholtz J M; Robertson J F; Thürlimann B; von Euler M; Sahmoud T; Webster A; Steinberg M;
Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma.
Cancer 2001;92(9):2247-58.
-
2001: Nabholtz J M; Riva A
The choice of adjuvant combination therapies with taxanes: rationale and issues addressed in ongoing studies.
Clinical breast cancer 2001;2 Suppl 1():S7-14.
-
2001: Buzdar A; Douma J; Davidson N; Elledge R; Morgan M; Smith R; Porter L; Nabholtz J; Xiang X; Brady C
Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(14):3357-66.
-
2001: Parliament M; Jha N; Rapp E; Smith C; MacKinnon J; Nabholtz J M; Hanson J; Reiman T; Mackey J
Concurrent weekly carboplatin and radiotherapy for nasopharyngeal carcinoma: report of a joint phase II study.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2001;58(2):131-6.
-
2001: Nabholtz J M; Mackey J R; Smylie M; Paterson A; Noël D R; Al-Tweigeri T; Tonkin K; North S; Azli N; Riva A
Phase II study of docetaxel, doxorubicin, and cyclophosphamide as first-line chemotherapy for metastatic breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(2):314-21.
-
2001: Nabholtz J M; Reese D M
Third-generation aromatase inhibitors in the treatment of advanced breast cancer.
Breast cancer (Tokyo, Japan) 2001;8(4):305-9.
-
2001: Conner-Spady B; Cumming C; Nabholtz J M; Jacobs P; Stewart D
Responsiveness of the EuroQol in breast cancer patients undergoing high dose chemotherapy.
Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation 2001;10(6):479-86.
-
2001: Nabholtz J M; Riva A
Taxane/anthracycline combinations: setting a new standard in breast cancer?
The oncologist 2001;6 Suppl 3():5-12.
-
2000: Nabholtz J M; Buzdar A; Pollak M; Harwin W; Burton G; Mangalik A; Steinberg M; Webster A; von Euler M
Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(22):3758-67.
-
2000: Nabholtz J M; North S; Smylie M; Mackey J; Au H J; Au R; Morrish D; Salter E; Tonkin K
Docetaxel (Taxotere) in combination with anthracyclines in the treatment of breast cancer.
Seminars in oncology 2000;27(2 Suppl 3):11-8.
-
2000: Nabholtz J M; Tonkin K; Smylie M; Au H J; Lindsay M A; Mackey J
Chemotherapy of breast cancer: are the taxanes going to change the natural history of breast cancer?
Expert opinion on pharmacotherapy 2000;1(2):187-206.
-
1999: Nabholtz J M
Docetaxel (Taxotere) plus doxorubicin-based combinations: the evidence of activity in breast cancer.
Seminars in oncology 1999;26(3 Suppl 9):7-13.
-
1999: Nabholtz J M; Smylie M; Mackey J; Au H J; Tonkin K; Au R; Morrish D; Salter E
Docetaxel and anthracycline polychemotherapy in the treatment of breast cancer.
Seminars in oncology 1999;26(3 Suppl 8):47-52.
-
1999: Nabholtz J M; Lindsay M A; Hugh J; Mackey J; Smylie M; Au H J; Tonkin K; Allen M
The academic global virtual concept in clinical cancer research and its application to breast cancer: The Breast Cancer International Research Group.
Seminars in oncology 1999;26(3 Suppl 8):4-8.
-
1999: Nabholtz J M
The role of taxanes in the management of breast cancer.
Seminars in oncology 1999;26(3 Suppl 8):1-3.
-
1999: Nabholtz J M; Senn H J; Bezwoda W R; Melnychuk D; Deschênes L; Douma J; Vandenberg T A; Rapoport B; Rosso R; Trillet-Lenoir V; Drbal J; Molino A; Nortier J W; Richel D J; Nagykalnai T; Siedlecki P; Wilking N; Genot J Y; Hupperets P S; Pannuti F; Skarlos D; Tomiak E M; Murawsky M; Alakl M; Aapro M
Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(5):1413-24.
-
1999: Janowska-Wieczorek A; Marquez L A; Nabholtz J M; Cabuhat M L; Montaño J; Chang H; Rozmus J; Russell J A; Edwards D R; Turner A R
Growth factors and cytokines upregulate gelatinase expression in bone marrow CD34(+) cells and their transmigration through reconstituted basement membrane.
Blood 1999;93(10):3379-90.
-
1999: Nabholtz J M; Tonkin K; Smylie M; Mackey J; Janowska-Wieczorek A
Review of docetaxel and doxorubicin-based combinations in the management of breast cancer: from metastatic to adjuvant setting.
Seminars in oncology 1999;26(1 Suppl 3):10-6.
-
1999: Vogel C L; Nabholtz J M
Monotherapy of metastatic breast cancer: a review of newer agents.
The oncologist 1999;4(1):17-33.
-
1998: Nabholtz J M; Crown J
Phase III studies of single-agent docetaxel in patients with metastatic breast cancer who have progressed despite previous chemotherapy regimens: preliminary results.
Seminars in oncology 1998;25(6 Suppl 13):4-9.
-
1998: Nabholtz J M; Mackey J; Smylie M; Tonkin K
Taxane-based three-drug combination in metastatic and adjuvant treatment of breast cancer.
Seminars in oncology 1998;25(5 Suppl 12):27-31.
-
1997: Nabholtz J M; Smylie M; Mackey J R; Noel D; Paterson A H; al-Tweigeri T; Au D; Sansregret E; Delorme F; Riva A
Docetaxel/doxorubicin/cyclophosphamide in the treatment of metastatic breast cancer.
Oncology (Williston Park, N.Y.) 1997;11(8 Suppl 8):37-41.
-
1997: Nabholtz J M; Thuerlimann B; Bezwoda W R; Melnychuk D; Deschênes L; Douma J; Vandenberg T A; Rapoport B; Rosso R; Trillet-Lenoir V; Drbal J; Aapro M S; Alaki M; Murawsky M; Riva A
Docetaxel vs mitomycin plus vinblastine in anthracycline-resistant metastatic breast cancer.
Oncology (Williston Park, N.Y.) 1997;11(8 Suppl 8):25-30.
-
1997: Nabholtz J M; Smylie M; Mackey J; Paterson A; Noel D; al-Tweigeri; Janowska A; Delorme F; Riva A
Docetaxel/doxorubicin/cyclophosphamide in the treatment of metastatic breast cancer.
Oncology (Williston Park, N.Y.) 1997;11(6 Suppl 6):25-7.
-
1997: Mackey J R; Desai S; Larratt L; Cwik V; Nabholtz J M
Myasthenia gravis in association with allogeneic bone marrow transplantation: clinical observations, therapeutic implications and review of literature.
Bone marrow transplantation 1997;19(9):939-42.
-
1996: al-Tweigeri T; Nabholtz J M; Mackey J R
Ocular toxicity and cancer chemotherapy. A review.
Cancer 1996;78(7):1359-73.
-
1995: Nabholtz J M; al-Tweigeri T; Jacquelin N; Venner P M
Autologous bone marrow support and bone disease in metastatic breast cancer.
The Canadian journal of oncology 1995;5 Suppl 1():33-9.
-
1995: Nabholtz J M; al-Tweigeri T; Jacquelin N; Venner P M
Autologous bone marrow support and bone disease in metastatic breast cancer.
The Canadian journal of oncology 1995;5(2):369-75.
-
1994: al Ahwal M; Jha N; Nabholtz J M; Hugh J; Birchall I; Nguyen G K
Olfactory neuroblastoma: report of a case associated with inappropriate antidiuretic hormone secretion.
The Journal of otolaryngology 1994;23(6):437-9.
-
1993: MacLean G D; Reddish M; Koganty R R; Wong T; Gandhi S; Smolenski M; Samuel J; Nabholtz J M; Longenecker B M
Immunization of breast cancer patients using a synthetic sialyl-Tn glycoconjugate plus Detox adjuvant.
Cancer immunology, immunotherapy : CII 1993;36(4):215-22.
Sign-in to see more
